<?xml version="1.0" encoding="UTF-8"?>
<p>Spike glycoprotein of SARS‐CoV‐2 contains a receptor‐binding domain (RBD) that recognizes the target receptor. The receptor angiotensin‐converting enzyme‐2 (ACE‐2) is a preferable receptor for SARS‐CoV‐2 (Peng et al., 
 <xref rid="ptr6893-bib-0056" ref-type="ref">2020</xref>). Furin blocks a spike protein of mouse hepatitis coronavirus required for attachment and fusion during infection (Bosch, van der Zee, de Haan, &amp; Rottier, 
 <xref rid="ptr6893-bib-0008" ref-type="ref">2003</xref>; de Haan, Stadler, Godeke, Bosch, &amp; Rottier, 
 <xref rid="ptr6893-bib-0018" ref-type="ref">2004</xref>). Emodin (
 <bold>67</bold>) (Figure 
 <xref rid="ptr6893-fig-0002" ref-type="fig">2e</xref>) inhibits the spike protein and ACE‐2 interaction preventing coronavirus entry (Ho et al., 
 <xref rid="ptr6893-bib-0022" ref-type="ref">2007</xref>). Secondary metabolites like hesperidin (
 <bold>15</bold>), pectolinarin (
 <bold>68</bold>), cannabinoids (
 <bold>69</bold>), rhoifolin (
 <bold>70</bold>), diosmin (
 <bold>71</bold>), apiin (
 <bold>72</bold>), diacetylcurcumin (
 <bold>73</bold>) (Figure 
 <xref rid="ptr6893-fig-0002" ref-type="fig">2e</xref>), epigallocatechin gallate (
 <bold>11</bold>), (E)‐1‐(2‐Hydroxy‐4‐methoxyphenyl)‐3‐[3‐[(E)‐3‐(2‐hydroxy‐4‐methoxyphenyl)‐3‐oxoprop‐1‐enyl]phenyl]prop‐2‐en‐1‐one (
 <bold>74</bold>), and beta,beta′‐(4‐Methoxy‐1,3‐phenylene)bis(2′‐hydroxy‐4′,6′‐dimethoxyacrylophenone (
 <bold>75</bold>) (Figure 
 <xref rid="ptr6893-fig-0002" ref-type="fig">2f</xref>) from medicinal plants are bioactive against SARS‐CoV‐2 main protease and spike glycoprotein so, it is necessary to screen all the available antiviral drugs against COVID‐19 for faster development of therapeutic option to control the pandemic (Adem, Eyupoglu, Sarfraz, Rasul, &amp; Ali, 
 <xref rid="ptr6893-bib-0002" ref-type="ref">2020</xref>; Peng et al., 
 <xref rid="ptr6893-bib-0056" ref-type="ref">2020</xref>).
</p>
